宫颈癌患者联合检测血清suPAR及SCCAg意义.docVIP

宫颈癌患者联合检测血清suPAR及SCCAg意义 　　[摘要] 目的 联合检测子宫颈癌患者血清中可溶性尿激酶受体(suPAR)及血清鳞状细胞癌抗原(SCC-Ag)水平,探讨其临床意义及两者的相关性。方法 通过酶联免疫吸附试验法(ELISA)检测60例宫颈癌患者及30例子宫肌瘤患者(对照组)血清中可溶性uPAR(suPAR)及血清鳞状细胞癌抗原(SCC-Ag)的水平。结果 宫颈浸润癌患者和宫颈原位癌患者血清suPAR水平均比子宫肌瘤患者(对照组)升高。具有统计学意义(P0.01);经SNK-q检验,与淋巴结转移及浸润程度有关,差异有统计学意义(P均0.05);与分化程度无关,差异无统计学意义;宫颈癌患者血清中SCC-Ag水平为(0.971+0.263 )μg/mL,与子宫肌瘤良性组对照比较显著升高,具有统计学意义(P0.01);宫颈癌患者血清suPAR水平与SCC-Ag水平存在正相关关系;同一宫颈癌患者术后半年血清suPAR水平明显低于术前血清suPAR水平,具有统计学意义(P0.01)。结论 联合检测宫颈癌患者血清中suPAR与SCC-Ag水平有助于判断患者的病情及预后,在临床上必将有着广阔的应用前景。 　　[关键词] 宫颈癌; 可溶性尿激酶受体; 血清鳞状细胞癌抗原; 酶联免疫吸附测定法 　　[中图分类号] R737.33 [文献标识码] A [文章编号] 1673-9701(2010)07-09-03 　　 　　Significance of Joint Detection of suPAR and SCC-Ag in Cervical Cancer 　　YAN Zhongping1 ZHENG Shumin2 　　1.Department of Postgraduate,Shanxi Medical University,Taiyuan 030001,China;2.Shanxi Provincial Tumor Hospital,Taiyuan 030001,China 　　 　　[Abstract] ObjectiveTo detect the levels of serum suPAR and SCC-Ag in cervical cancer and investigate their correlation and clinical application. MethodsThe levels of serum suPAR and SCC-Ag were measured by ELISA in 30 cases of benign uterine leiomyoma(control group)and 60 cases of cervical cancer. ResultsThe serum suPAR levels in both invasive carcinoma of cervix and carcinoma in situ of cervix were higher than those of control group,with a significant difference between them(P0.01). The SNK-q test showed the serum suPAR level was correlated with the degree of lymph node metastasis and invasion,with a significant difference(P0.05),but the level had no correlation with the degree of differentiation,with no significant difference. The serum SCC-Ag level in cervical cancer was(0.971±0.263)μg/mL,significantly higher than that in benign uterine leiomyoma,with a significant difference between on them(P0.01). There was a positive correlation between the serum suPAR level and the serum SCC-Ag level in cervical cancer. The serum suPAR level half-year after treatment was higher than that before treatment,with a significant